• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Biohaven Licensing Deal At Ono Pharmaceutical Stock Has Changed Its Investment Story

    Simply Wall St·10/09/2026 18:24:18
    Listen to the news
    • Biohaven announced in October 2026 that Ono Pharmaceutical secured exclusive rights to develop and commercialize Biohaven's MoDE pan IgG degrader portfolio, including Phase 3 asset BHV-1300 and follow-ons BHV-1310 and BHV-1320, across Japan, South Korea, Taiwan, and ASEAN markets.
    • The arrangement gives Ono Pharmaceutical regional access to a new extracellular protein degrader platform for IgG mediated autoimmune diseases, while Biohaven receives up to US$100 million in near term payments and about 20% royalties on future net sales in the licensed territories.
    • We now examine how this regional MoDE degrader licensing deal could influence Ono Pharmaceutical's broader investment narrative and pipeline positioning.

    Scan how Ono Pharmaceutical's autoimmune push compares to peers by reviewing a curated group of 9 healthcare AI stocks targeting next generation therapies and data driven drug development.

    What Is Ono Pharmaceutical's Investment Narrative?

    To own Ono Pharmaceutical, you have to buy into a fairly simple idea. This is a mature oncology and specialty drug developer that still wants new engines of revenue, while market forecasts point to modest declines in revenue and earnings over the next few years. The MoDE IgG degrader deal with Biohaven fits that story. Ono is not taking on global risk for BHV-1300, yet it gains access to a differentiated autoimmune platform in its home region, which speaks directly to execution and pipeline depth rather than financial engineering.

    In the near term, the thesis still rests on how well existing oncology and chronic disease products hold up on pricing and demand, backed by high quality earnings, healthier profit margins than last year, and a 3.54% dividend that many holders treat as a key part of the return profile. The Biohaven agreement may not transform group revenue quickly, but it can refresh the medium term catalyst list if trials and launches in Asia progress cleanly, especially with analysts already seeing the shares trade about 34.1% below one fair value estimate and at a P/E that is only slightly below peers.

    Yet there is a quieter issue in the Ono Pharmaceutical story that keeps coming back to one uncomfortable question about...

    There's only one way to know the right time to buy, sell or hold Ono Pharmaceutical. Head to Simply Wall St's company report for the latest analysis of Ono Pharmaceutical's Fair Value.

    TSE:4528 1-Year Stock Price Chart
    TSE:4528 1-Year Stock Price Chart

    Exploring Other Perspectives

    Two fair value estimates from the Simply Wall St Community span roughly ¥2,516 to ¥3,427 per share, which illustrates how far apart private investors can land on Ono Pharmaceutical. These views were set before the Biohaven MoDE IgG degrader agreement, so treat them as a starting point and explore multiple angles before deciding how this story fits your own portfolio.

    Explore another Ono Pharmaceutical fair value estimate, including one that suggests as much as 52% upside from the current price.

    Decide For Yourself

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Ono Pharmaceutical?

    Once you have formed a view on Ono Pharmaceutical, it often helps to set that opinion against a wider watchlist of potential opportunities.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.